ClinicalTrials.gg
Not yet recruitingNCT04957862Updated Aug 10, 2022

Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage

An interventional study of Robotic Assisted Evacuation in Hypertensive Intracerebral Hemorrhage, sponsored by Shanghai Changzheng Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-10.

Sponsored by Shanghai Changzheng Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
428
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage for Accelerating Functional Rehabilitation (RESCUE-CHAIN): a Multi-center Randomized Controlled Trial

Read the detailed description

Background: Hypertensive intracerebral hemorrhage (HICH) is a devastating neurological disorder with high mortality and disability rates. Secondary injury following HICH may worsen motor function rehabilitation in subacute and chronic hematoma. Hematoma evacuation has the potential to reduce mass effect and mitigate the neurotoxic effects. A per-protocol analysis identified a significant functional improvement in patients with minimally invasive surgery with thrombolysis achieving end of treatment (EOT) goal ≤ 15mL. However, no surgical management of stabilized subacute or chronic HICH have been reported before. Therefore, we design this study in which we hypothesize this robotic assisted approach to hematoma EOT goal ≤ 15mL would accelerate functional rehabilitation in subacute and chronic HICH patients.

02

Conditions studied

  • Hypertensive Intracerebral Hemorrhage

Keywords

  • Randomized controlled trial
  • Hypertensive Intracerebral Hemorrhage
  • subacute
  • chronic
  • robotic assisted evacuation
  • function rehabilitation
03

In context

Intracranial Hemorrhage, Hypertensive

23 studies on the registry are indexed under Intracranial Hemorrhage, Hypertensive; 8 are open to participants now.

This study's planned enrollment of 428 is above the median of 306 across 17 interventional studies indexed under Intracranial Hemorrhage, Hypertensive.

Browse Intracranial Hemorrhage, Hypertensive studies →

Lead sponsor

Shanghai Changzheng Hospital is the lead sponsor of 128 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The inclusion criteria are HICH patients who: (1) are ≥ 18 and ≤ 75 years old of either gender; (2) have evidence of supratentorial, deep-seated on CT scan with a volume of between 15 mL and 30 mL; (3) are within 24 h of ictus (\<24 h between symptom onset and initial imaging); (4) have stable hematoma (hematoma growth\<5 mL) for at least 12 h after diagnostic CT; (5) have no brain herniation and no needs for emergency surgery (clinical decisions made by 2 attending neurosurgeons); (6) have had no previous surgery on HICH or traumatic brain injury; (7) have GCS>8, NIH Stroke Scale (NIHSS)>5, Modified Rankin Scale (mRS) 3-5, and FMA scale\<85; (8) fully understand the nature of the study and have signed .

The exclusion criteria are: (1) HICH caused by aneurysms, cerebrovascular malformations, tumors or trauma; (2) any pre-existing physical or mental disorder that could interfere with the functional assessment; (3) severe abnormal coagulation function, hematologic diseases or multiple hemorrhagic lesions; (4) excessive hematoma extending into the ventricular system with ventricular dilation; (5) concomitant diseases such as liver, kidney and heart failure; (6) rebleeding>5 mL or with surgical indications before allocation; (7) poor adherence or other unsuitable situations for the trial as determined by the investigators; (8) pregnant female.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
428 participants (estimated)

Study arms

  • Active comparator
    robotic assisted evacuation

    In the intervention arm, patients will receive stereotactic robotic assisted HICH evacuation according to the protocol under general anesthesia.

    Procedure: Robotic Assisted Evacuation

  • No intervention
    Concomitant care

    All enrolled HICH patients in this study will receive standard medical treatment in the first 3-4 weeks according to the ASA/AHA guideline . Continued medical treatment is applied to patients in the control arm. Both arms will receive identical rehabilitation therapy three times per week for 180 days at one facility. Rehabilitation therapy includes identical physical therapy, occupational therapy, speech therapy, functional training, acupuncture and massage.

Interventions

  • ProcedureRobotic Assisted Evacuation

    On the day of surgery, the patient is placed in the prone position. After the Mayfield skull clamp is positioned to reduce interference, the videometric tracker of robot will automatically scan the preliminary markers to complete patient-to-image registration. Following the registration, the robotic arm will move on command according to the planned puncture trajectory and stop at a defined distance to the marked target point. The entry point is marked on the scalp along the puncture trajectory, then a scalp incision and burr-hole drilling will be performed. After penetrating the dura with unipolar electrocautery, a drainage tube will be gently inserted to the defined depth under the indication of the disinfected robotic arm. The liquefied hematoma will be withdrawn slowly by a 10 mL syringe.

06

What researchers measure

Primary outcomes

  1. modified Rankin Scale (mRS) 0-2

    The modified Rankin Scale (mRS) is a single item, global outcomes rating scale for patients post-stroke. It is used to categorize level of functional independence with reference to pre-stroke activities rather than on observed performance of a specific task.

    Time frame: 180 days after surgery

Secondary outcomes

  1. Evacuation rate of HICH

    the ratio of effective volume reduction to the initial volume

    Time frame: at the first day after procedure, 30 days and 180 days during the follow-up period.

  2. modified Rankin Scale (mRS) 0-1

    The modified Rankin Scale (mRS) is a single item, global outcomes rating scale for patients post-stroke. It is used to categorize level of functional independence with reference to pre-stroke activities rather than on observed performance of a specific task.

    Time frame: 180 days after surgery

  3. between-group shift analysis in the mRS distribution

    The modified Rankin Scale (mRS) is a single item, global outcomes rating scale for patients post-stroke. It is used to categorize level of functional independence with reference to pre-stroke activities rather than on observed performance of a specific task.

    Time frame: 180 days after surgery

  4. Extended Glasgow Outcome Scale (eGOS)

    The GOS-E adds to the original 5 GOS categories, with 3 additional categories. The 8 categories are: Dead, Vegetative State, Lower Severe Disability, Upper Severe Disability, Lower Moderate Disability, Upper Moderate Disability, Lower Good Recovery, and Upper Good Recovery.

    Time frame: at 90- and 180-days after surgery.

  5. NIH Stroke Scale(NIHSS)

    The NIHSS is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The single patient assessment requires less than 10 minutes to complete. The evaluation of stroke severity depends upon the ability of the observer to accurately and consistently assess the patient

    Time frame: at 90- and 180-days after surgery.

  6. Barthel Index for Activities of Daily Living (ADL-BI)

    The Barthel Index (BI) measures the extent to which somebody can function independently and has mobility in their activities of daily living (ADL) i.e. feeding, bathing, grooming, dressing, bowel control, bladder control, toileting, chair transfer, ambulation and stair climbing. The index also indicates the need for assistance in care.

    Time frame: at 90- and 180-days after surgery.

  7. Fugl-Meyer Assessment (FMA)

    The FMA motor assessments for the upper (maximum score 66 points) and lower extremity (maximum score 34 points) are recommended as core measures to be used in every stroke recovery and rehabilitation trial.

    Time frame: at 90- and 180-days after surgery.

  8. Motor Assessment Scale (MAS)

    The MAS is comprised of 8 items corresponding to 8 areas of motor function. Patients perform each task 3 times and the best performance is recorded. Supine to side lying Supine to sitting over the edge of a bed Balanced sitting Sitting to standing Walking Upper-arm function Hand movements Advanced hand activities

    Time frame: at 90- and 180-days after surgery.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2022; primary completion for Dec 2024, 27 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2021
First posted
Jul 12, 2021
StartEst.
Sep 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 30, 2025
Last update
Aug 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04957862
Collaborators
Beijing Tian Tan Hospital Affiliated to Capital Medical University, Tianjin Medical University General Hospital, Peking Union Medical College Hospital, First Affiliated Hospital of Harbin Medical University, Renmin Hospital of Wuhan University, South Taihu Hospital of Huzhou, Qian Xi Nan People's Hospital, Huazhong University of Science and Technology Union Hospital (Nanshan Hospital), Fujian Provincial Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, LanZhou University, Anhui No.2 Provincial People's Hospital, First Affiliated Hospital of Wenzhou Medical University, Jinjiang Hospital of Traditional Chinese Medicine, Tang-Du Hospital, Wuhan Union Hospital, China, Shenzhen People's Hospital, Shaanxi Provincial People's Hospital, Shanghai 6th People's Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, Sanhe Yanjiao People's Hospital, General Hospital of Ningxia Medical University, Affiliated Hospital of Chifeng University, Haikou People's Hospital, Qilu Hospital of Shandong University, Xiangya Hospital of Central South University
Responsible party
Hou Lijun (Professor, Shanghai Changzheng Hospital) — Principal investigator
First posted
Jul 12, 2021
Start date
Sep 1, 2022 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Aug 10, 2022

Study contacts

Lijun Hou, MD,PhD
Contact
houlijun@smmu.com
+862181885671
Rongbin Chen, MD,PhD
Contact
crb2588@163.com
+862181885686
Lijun Hou, MD,PhD
principal investigator · Shanghai Changzheng Hospital
Tao Xu, MD,PhD
study director · Shanghai Changzheng Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion